Edwards Lifesciences Corporation — Q3 2023 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2023. Unaudited results; dollar amounts in millions except per-share data. Edwards develops and sells medical technologies for structural heart disease and critical care monitoring.
Financial performance and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Net sales | $1,480.9 | $1,319.0 | $4,470.7 | $4,034.1 |
| Gross profit | $1,130.5 | $1,065.2 | $3,447.8 | $3,211.6 |
| Operating income | $418.4 | $402.4 | $1,134.0 | $1,300.7 |
| Net income attributable to Edwards | $384.9 | $343.5 | $1,032.5 | $1,123.5 |
| Diluted EPS | $0.63 | $0.55 | $1.69 | $1.79 |
- Q3 sales grew 12.3% year over year; nine-month sales grew 10.8%. TAVR remained the largest product group, with nine-month sales of $2,900.4, up 9.4%. TMTT sales increased 67.3% to $141.6.
- Gross margin was approximately 76.3% in Q3 versus 80.8% a year earlier. Management attributed the decline to foreign-exchange effects, which reduced gross margin by 4.1 percentage points in the quarter and 2.3 points year to date.
- Q3 operating income increased 4.0%, while nine-month operating income declined 12.8%. The nine-month comparison includes $193.6 of intellectual-property agreement and litigation expense in 2023, compared with $10.8 in 2022; 2022 also included a $66.8 special charge.
- Cash provided by operations was $759.2 for the first nine months, down from $935.4. Management cited the $300 Medtronic agreement payment as the primary reason for the decline. Capital expenditures were $164.7.
- At September 30, cash and cash equivalents were $1,410.1 and short-term investments were $453.8. Current assets were $4,067.5 and current liabilities $1,238.9. Long-term debt was $596.8; no amounts were drawn on the $750 revolving credit facility.
- Total assets were $9,370.8 and stockholders’ equity was $6,727.1. Edwards repurchased $431.2 of shares during the nine-month period.
Changes, outlook, and notable developments
- Sales increased across all product groups in Q3. Nine-month U.S. and European sales each grew 11.9%; Japan declined 6.1%, with management citing pandemic-related effects and currency pressures among broader operating challenges.
- The company reported continued enrollment in TAVR and TMTT clinical trials, including PROGRESS and ALLIANCE, and completion of enrollment in the ENCIRCLE and TRISCEND II pivotal trials. In October 2023, after quarter-end, Edwards reported CE Mark approval for EVOQUE in Europe and MITRIS RESILIA, and approval in Japan for PASCAL Precision.
- Under its April 2023 agreement with Medtronic, Edwards paid $300 for a 15-year global covenant not to sue concerning certain structural-heart patents and agreed to annual royalties tied to sales of certain products. It recorded charges of $37 in March and $139 in April for the agreement.
- Edwards acquired a 61% interest in a medical technology company in February 2023 and has an option to acquire the remaining interest. The company develops technologies to detect and manage cardiovascular disease; pro forma results were not presented because the acquired business was not material to Edwards’ consolidated results.
- The filing provides no specific forward revenue or earnings guidance. Management said cash, investments, operating cash flow, and available credit were sufficient for current and long-term requirements, while noting uncertainty from macroeconomic conditions and ongoing COVID-19-related effects, including staffing and Japan market impacts.
Risks, contingencies, and unusual items
- Tax dispute: The IRS proposed adjustments to 2015–2017 intercompany royalty transactions that could result in approximately $220 of additional tax expense. Administrative discussions did not produce a satisfactory resolution; Edwards plans to contest the matter in court. Related 2018–2023 transactions remain under examination, and the company says the potential impact could be significant but cannot be reasonably estimated.
- Other investigations and litigation: An FCPA investigation involving activities in Japan and other markets remains ongoing; the outcome and potential financial impact are unclear. A patent-infringement lawsuit concerning SAPIEN 3 Ultra has no recorded accrual because the company cannot estimate exposure. Edwards says other lawsuits could materially affect results in an individual period.
- Operating risks: Management identifies competition, product development and adoption, regulatory approvals, supply-chain and manufacturing issues, staffing, currency movements, inflation and interest rates as risks. It reported no material changes to previously disclosed risk factors.
- Investment debt securities had $38.7 of gross unrealized losses, which the company attributed largely to interest rates and considered temporary. The filing also reports $1.0 billion of debt-security investments and $109.8 of investments in unconsolidated entities.
Investor verification points
- Assess whether sales growth—particularly TAVR and rapidly growing TMTT—can offset currency effects and the decline in gross margin.
- Track the Medtronic agreement’s ongoing royalty expense and cash-flow effects, alongside the one-time charges already recorded.
- Monitor the IRS transfer-pricing dispute, related tax examinations, and the $542.9 gross uncertain-tax-position liability disclosed at September 30, 2023.
- Review operating cash conversion and working-capital trends, including the increase in inventory to $1,032.4 from $875.5 at year-end 2022.
- Follow clinical trial, regulatory, and commercial progress for TAVR, TMTT, and acquired technologies, as well as the FCPA investigation and patent litigation.